Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 0.63 |
| ▸ | THRB | P10828 | 19/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24548623 | 0.89 | THRB (0.51) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL24548726 | 0.82 | THRB (0.49) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL16919814 | 0.80 | THRA (0.68) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL32675681 | 0.80 | THRA (0.64) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749414 | 0.79 | THRA (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749523 | 0.79 | THRA (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL2926289 | 0.79 | THRB (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840300 | 0.78 | THRA (0.65) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749359 | 0.77 | THRA (1.00) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL30970994 | 0.77 | THRA (0.66) | THRATHRBCYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2022127779-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | 山东第一医科大学(山东省医学科学院) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127779-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | 山东第一医科大学(山东省医学科学院) | 2022-06-23 | — | — | WO | disclosed |
| CN-112645936-B | Substituted pyridazinone compound and use thereof | 山东第一医科大学(山东省医学科学院) | 2022-03-01 | — | — | CN | disclosed |
| CN-112645936-A | Substituted pyridazinone compound and use thereof | 山东第一医科大学(山东省医学科学院) | 2021-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | THRB, TPO, TSHR | THRA 4/4885THRB 1/4885CYP2C9 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.